Palatin Technologies

Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
Palatin Technologies | Resources

Resources

Informative Resources

Characterization of the Melanocortin Receptor 4 Oral Small Molecule Agonist PL7737

Co-Administration of Bremelanotide With Tirzepatide in Participants With Obesity

Activating the Melanocortin System Resolves Inflammation, Reduces VEGF Signaling in Diabetic Retinopathy (DR), and Provides Retinal Ganglion Cell (RGC) Protection

Efficacy and Safety of PL9643 in Dry Eye Disease: Results From a Phase 3, Randomized, Vehicle-Controlled Study

Activation of the Melanocortin System Increases Aqueous Outflow, Reduces Intraocular Pressure (IOP), and Protects Neurons in Glaucoma Models

Efficacy of Bremelanotide (BMT) to Stabilize Podocyte Function and Reduce Proteinuria in Adults with Type II Diabetic Nephropathy: Results from a Phase IIb, Open-Label Study

Melanocortin Agonist PL7737 Causes Weight Loss and Decreases Food Consumption in Obese Mice

Harnessing the Melanocortin System to Heal Inflammatory Diseases

Structural Modifications Allow the Removal of Melanocortin Receptor 1 Agonism From Melanocortin Receptor 4 Agonists

Virtual KOL Event: Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance